{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:39:20Z","timestamp":1785537560797,"version":"3.56.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10430072010004"],"award-info":[{"award-number":["10430072010004"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.vaccine.2025.128079","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T19:19:23Z","timestamp":1766603963000},"page":"128079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Antibody concentration and function following SARS-CoV-2 vaccination decrease with age in adults and children with Down syndrome"],"prefix":"10.1016","volume":"73","author":[{"given":"Bianca M.M.","family":"Streng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lobke C.M.","family":"Hensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline M.","family":"Delemarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob S.","family":"Binnendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaby","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerco","family":"den Hartog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona R.","family":"van der Klis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit J.","family":"van Gils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia M.W.","family":"Coppus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel E.","family":"Weijerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Lamberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis J.","family":"Bont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne G.","family":"Wildenbeest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.128079_bb0005","first-page":"33","article-title":"Medical vulnerability of individuals with down syndrome to severe COVID-19\u2013data from the trisomy 21 research society and the UK ISARIC4C survey","author":"H\u00fcls","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"October","key":"10.1016\/j.vaccine.2025.128079_bb0010","first-page":"1","article-title":"COVID-19 mortality risk in down syndrome\u00a0: results from a cohort study of 8 million adults","author":"Clift","year":"2020","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128079_bb0015","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41436-020-01004-w","article-title":"Individuals with down syndrome hospitalized with COVID-19 have more severe disease","volume":"23","author":"Malle","year":"2021","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128079_bb0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ridd.2011.09.026","article-title":"Morbidity and hospitalizations of adults with down syndrome","volume":"33","author":"Tenenbaum","year":"2012","journal-title":"Res Dev Disabil"},{"issue":"10","key":"10.1016\/j.vaccine.2025.128079_bb0025","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/pd.6003","article-title":"Does non-invasive prenatal testing affect the livebirth prevalence of down syndrome in the Netherlands? A population-based register study","volume":"41","author":"de Groot-van der Mooren","year":"2021","journal-title":"Prenat Diagn"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128079_bb0030","first-page":"139","article-title":"Prevalence and clinical picture of celiac disease in Italian down syndrome patients: a multicenter study","volume":"33","author":"Bonamico","year":"2001","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.vaccine.2025.128079_bb0035","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00125-006-0231-6","article-title":"Increased prevalence of down\u2019s syndrome in individuals with type 1 diabetes in Denmark: a nationwide population-based study","volume":"49","author":"Bergholdt","year":"2006","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.vaccine.2025.128079_bb0040","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00431-023-04890-9","article-title":"Clinical practice \u2014 latest insights in optimizing the care of children with down syndrome","volume":"182","author":"van Gameren-Oosterom","year":"2023","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2025.128079_bb0045","series-title":"A genetic cause of Alzheimer disease: Mechanistic insights from Down syndrome. Vol. 16, Nature Reviews Neuroscience","first-page":"564","author":"Wiseman","year":"2015"},{"key":"10.1016\/j.vaccine.2025.128079_bb0050","series-title":"A genetic cause of Alzheimer disease: Mechanistic insights from Down syndrome. Vol. 16, Nature Reviews Neuroscience","first-page":"564","author":"Wiseman","year":"2015"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128079_bb0055","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/alz.12799","article-title":"Complement dysregulation and Alzheimer\u2019s disease in down syndrome","volume":"19","author":"Veteleanu","year":"2023","journal-title":"Alzheimer\u2019s and Dementia"},{"issue":"7","key":"10.1016\/j.vaccine.2025.128079_bb0060","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13652","article-title":"Accelerated epigenetic aging in newborns with down syndrome","volume":"21","author":"Xu","year":"2022","journal-title":"Aging Cell"},{"issue":"6","key":"10.1016\/j.vaccine.2025.128079_bb0065","first-page":"538","article-title":"Down syndrome: is it really characterized by precocious Immunosenescence?","volume":"2","author":"Kusters","year":"2011","journal-title":"Aging Dis"},{"key":"10.1016\/j.vaccine.2025.128079_bb0070","doi-asserted-by":"crossref","DOI":"10.1186\/1742-4933-8-4","article-title":"Inflammatory and immunological parameters in adults with down syndrome","volume":"8","author":"Trotta","year":"2011","journal-title":"Immun Ageing"},{"key":"10.1016\/j.vaccine.2025.128079_bb0080","author":"Murray"},{"issue":"10","key":"10.1016\/j.vaccine.2025.128079_bb0085","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1021\/acs.jproteome.5b00356","article-title":"Plasma N-Glycome signature of down syndrome","volume":"14","author":"Borelli","year":"2015","journal-title":"J Proteome Res"},{"issue":"5","key":"10.1016\/j.vaccine.2025.128079_bb0090","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00281-020-00804-1","article-title":"Down syndrome, accelerated aging and immunosenescence","volume":"42","author":"Gensous","year":"2020","journal-title":"Semin Immunopathol"},{"issue":"6","key":"10.1016\/j.vaccine.2025.128079_bb0095","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jpeds.2005.07.022","article-title":"Intrinsic abnormalities of lymphocyte counts in children with down syndrome","volume":"147","author":"de Hingh","year":"2005","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.vaccine.2025.128079_bb0100","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jpeds.2009.12.006","article-title":"Distinct abnormalities in the innate immune system of children with down syndrome","volume":"156","author":"Bloemers","year":"2010","journal-title":"Journal of Pediatrics [Internet]"},{"issue":"19","key":"10.1016\/j.vaccine.2025.128079_bb0105","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.vaccine.2011.02.094","article-title":"Antibody responses to natural influenza a\/H1N1\/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children","volume":"29","author":"Meier","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2025.128079_bb0110","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/INF.0b013e3182737410","article-title":"Influenza a\/H1N1 vaccination response is inadequate in down syndrome children when the latest cut-off values are used","volume":"31","author":"Kusters","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.vaccine.2025.128079_bb0115","article-title":"Adults with trisomy 21 have differential antibody responses to influenza a","volume":"10","author":"James","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"10.1016\/j.vaccine.2025.128079_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2010.05.007","article-title":"Increased risk of respiratory tract infections in children with down syndrome: the consequence of an altered immune system","volume":"12","author":"Bloemers","year":"2010","journal-title":"Microbes Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128079_bb0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s15010-020-01408-5","article-title":"Respiratory tract infection-related healthcare utilisation in children with down\u2019s syndrome","volume":"48","author":"Manikam","year":"2020","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2025.128079_bb0130","first-page":"12","article-title":"Immune dysregulation and the increased risk of complications and mortality following respiratory tract infections in adults with down syndrome","author":"Illouz","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128079_bb0135","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-0225","article-title":"Down syndrome and the risk of severe RSV infection: a Meta-analysis","volume":"142","author":"Beckhaus","year":"2018","journal-title":"Pediatrics"},{"issue":"August 2020","key":"10.1016\/j.vaccine.2025.128079_bb0140","article-title":"Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination\u00a0: national prospective cohort study","volume":"374","author":"Hippisley-cox","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128079_bb0145","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41467-023-44276-x","article-title":"Risk of COVID-19 death in adults who received booster COVID-19 vaccinations in England","volume":"15","author":"Ward","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.128079_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100816","article-title":"Risk of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national prospective cohort studies involving 7.4 million adults in England, Northern Ireland, Scotland and Wales","volume":"37","author":"Bedston","year":"2024","journal-title":"The Lancet Regional Health - Europe"},{"issue":"21","key":"10.1016\/j.vaccine.2025.128079_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10215125","article-title":"Covid-19 in children with down syndrome: data from the trisomy 21 research society survey","volume":"10","author":"Emes","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.vaccine.2025.128079_bb0160","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.12.05044","article-title":"Risk of COVID-19 hospitalizations among school-aged children in Scotland: a national incident cohort study","volume":"12","author":"Shi","year":"2022","journal-title":"J Glob Health"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128079_bb0165","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3201\/eid2901.220530","article-title":"Risk for severe illness and death among pediatric patients with down syndrome hospitalized for COVID-19","volume":"29","author":"Leung","year":"2023","journal-title":"Brazil Emerg Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2025.128079_bb0170","doi-asserted-by":"crossref","first-page":"1155.e1","DOI":"10.1016\/j.cmi.2022.04.008","article-title":"SARS-CoV-2 vaccine humoral response in adults with down syndrome","volume":"28","author":"Sali","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128079_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11030694","article-title":"Safety and long-term immunogenicity of BNT162b2 vaccine in individuals with down syndrome","volume":"11","author":"Valentini","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128079_bb0180","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1093\/cid\/ciac590","article-title":"Development of an effective immune response in adults with down syndrome after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination","volume":"76","author":"Esparcia-Pinedo","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128079_bb0185","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/infdis\/jiac235","article-title":"Decreased antibody response after severe acute respiratory syndrome coronavirus 2 vaccination in patients with down syndrome","volume":"226","author":"Streng","year":"2022","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2025.128079_bb0190","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/infdis\/jiaa479","article-title":"SARS-CoV-2-specific antibody detection for Seroepidemiology: a multiplex analysis approach accounting for accurate Seroprevalence","volume":"222","author":"Den Hartog","year":"2020","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2025.128079_bb0195","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/cid\/ciab172","article-title":"Persistence of antibodies to severe acute respiratory syndrome coronavirus 2 in relation to symptoms in a nationwide prospective study","volume":"73","author":"den Hartog","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128079_bb0200","doi-asserted-by":"crossref","unstructured":"Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, et al. SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. Vol. vol. 6, Sci Immunol 2021.","DOI":"10.1126\/sciimmunol.abj1750"},{"issue":"15","key":"10.1016\/j.vaccine.2025.128079_bb0205","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.vaccine.2022.03.009","article-title":"Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: a complementary tool to detect breakthrough infections after COVID-19 vaccination?","volume":"40","author":"van den Hoogen","year":"2022","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2025.128079_bb0210","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201181","article-title":"Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses","volume":"217","author":"Schmidt","year":"2020","journal-title":"J Exp Med"},{"issue":"36","key":"10.1016\/j.vaccine.2025.128079_bb0215","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj5365","article-title":"Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination","volume":"7","author":"Caniels","year":"2021","journal-title":"Sci Adv"},{"issue":"7","key":"10.1016\/j.vaccine.2025.128079_bb0220","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.4049\/jimmunol.1001700","article-title":"Decreased Thymic output accounts for decreased naive T cell numbers in children with down syndrome","volume":"186","author":"Bloemers","year":"2011","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2025.128079_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2009.12.006","article-title":"Distinct abnormalities in the innate immune system of children with down syndrome","volume":"156","author":"Bloemers","year":"2010","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.vaccine.2025.128079_bb0230","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10875-020-00805-7","article-title":"Inborn errors of adaptive immunity in down syndrome","volume":"40","author":"Verstegen","year":"2020","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128079_bb0235","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/imr.13296","article-title":"The immune system in down syndrome: autoimmunity and severe infections","volume":"322","author":"Ramba","year":"2024","journal-title":"Immunol Rev"},{"issue":"26","key":"10.1016\/j.vaccine.2025.128079_bb0240","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg6218","article-title":"Multidimensional definition of the interferonopathy of down syndrome and its response to JAK inhibition","volume":"9","author":"Galbraith","year":"2023","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128079_bb0245","doi-asserted-by":"crossref","first-page":"64","DOI":"10.17294\/2330-0698.1876","article-title":"Prevalence of infectious diseases among 6078 individuals with down syndrome in the United States","volume":"9","author":"Fitzpatrick","year":"2022","journal-title":"J Patient Cent Res Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128079_bb0250","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128079_bb0255","first-page":"154","article-title":"Effect of a SARS-CoV-2 booster vaccine dose on the immune response of adults with down syndrome","volume":"86","author":"Yarci-Carri\u00f3n","year":"2023","journal-title":"J Inf Secur"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128079_bb0260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128079_bb0265","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/vaccines10020177","article-title":"Waning of anti-SARS-CoV-2 spike antibody levels 100 to 200 days after the second dose of the BNT162b2 vaccine","volume":"10","author":"Matsunaga","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128079_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266958","article-title":"Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: a mixed effects model across two vaccination periods","volume":"17","author":"Anastassopoulou","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.vaccine.2025.128079_bb0275","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/vaccines9050522","article-title":"The gender impact assessment among healthcare workers in the SARS-CoV-2 vaccination\u2014an analysis of serological response and side effects","volume":"9","author":"Di Resta","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128079_bib276","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2583416","article-title":"T-cell responses to SARS-CoV-2 vaccinations in adults with Down syndrome - a prospective cohort study","volume":"21","author":"Hensen","year":"2025","journal-title":"Human Vaccines & Immunotherapeutics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25013775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25013775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:04:11Z","timestamp":1770282251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25013775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":55,"alternative-id":["S0264410X25013775"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128079","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody concentration and function following SARS-CoV-2 vaccination decrease with age in adults and children with Down syndrome","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128079"}}